Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Neurocrine (NBIX) on February 13 and set a price target of $127. The company’s shares closed on Friday at $84.32.
According to TipRanks.com, Duncan is a 3-star analyst with an average return of 1.5% and a 47.2% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neurocrine with a $105.15 average price target, a 24.7% upside from current levels. In a report issued on January 30, H.C. Wainwright also reiterated a Buy rating on the stock with a $102 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $126.98 and a one-year low of $64.72. Currently, Neurocrine has an average volume of 1.25M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.
Read More on NBIX:
